28 August 2013 - Deborah Wilkes
Archived
Akorn is set to pay US$640 million for Hi-Tech Pharmacal, and plans to use the company's manufacturing capabilities to expand its private-label OTC business.
New to OTCToolbox?
This is available as part of an Annual Subscription to the OTCToolbox website.